Antigenic and sequence diversity at the C-terminus of the merozoite surface protein-1 from rodent malaria isolates, and the binding of protective monoclonal antibodies
- PMID: 10593171
- DOI: 10.1016/s0166-6851(99)00142-5
Antigenic and sequence diversity at the C-terminus of the merozoite surface protein-1 from rodent malaria isolates, and the binding of protective monoclonal antibodies
Abstract
Merozoite surface protein-1 (MSP-1) is a major candidate in the development of a vaccine against malaria. Immunisation with a recombinant fusion protein containing the two Plasmodium yoelii MSP-1 C-terminal epidermal growth factor-like domains (MSP-1(19)) can protect mice against homologous but not heterologous challenge, and therefore, antigenic differences resulting from sequence diversity in MSP-1(19) may be crucial in determining the potential of this protein as a vaccine. Representative sequence variants from a number of distinct P. yoelii isolates were expressed in Escherichia coli and the resulting recombinant proteins were screened for binding to a panel of monoclonal antibodies (Mabs) capable of suppressing a P. yoelii YM challenge infection in passive immunisation experiments. The sequence polymorphisms affected the binding of the antibodies to the recombinant proteins. None of the Mabs recognised MSP-1(19) of P. yoelii yoelii 2CL or 33X or P. yoelii nigeriensis N67. The epitopes recognised by the Mabs were further distinguished by their reactivity with the other fusion proteins. The extent of sequence variation in MSP-1(19) among the isolates was extensive, with differences detected at 35 out of the 96 positions compared. Using the 3-dimensional structure of the Plasmodium falciparum MSP-1(19) as a model, the locations of the amino acid substitutions that may affect Mab binding were identified. The DNA sequence of MSP-1(19) from two Plasmodium vinckei isolates was also cloned and the deduced amino acid sequence compared with that in other species.
Similar articles
-
Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain.Infect Immun. 2004 Oct;72(10):5840-9. doi: 10.1128/IAI.72.10.5840-5849.2004. Infect Immun. 2004. PMID: 15385485 Free PMC article.
-
Suppressive and additive effects in protection mediated by combinations of monoclonal antibodies specific for merozoite surface protein 1 of Plasmodium yoelii.Malar J. 2010 Feb 10;9:46. doi: 10.1186/1475-2875-9-46. Malar J. 2010. PMID: 20146804 Free PMC article.
-
Enhanced protection against malaria by a chimeric merozoite surface protein vaccine.Infect Immun. 2007 Mar;75(3):1349-58. doi: 10.1128/IAI.01467-06. Epub 2006 Dec 11. Infect Immun. 2007. PMID: 17158895 Free PMC article.
-
Plasmodium: immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge.Exp Parasitol. 1999 Jan;91(1):78-85. doi: 10.1006/expr.1999.4357. Exp Parasitol. 1999. PMID: 9920045
-
Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria.Parassitologia. 1999 Sep;41(1-3):409-14. Parassitologia. 1999. PMID: 10697894 Review.
Cited by
-
Antimalarial activity of cupredoxins: the interaction of Plasmodium merozoite surface protein 119 (MSP119) and rusticyanin.J Biol Chem. 2013 Jul 19;288(29):20896-20907. doi: 10.1074/jbc.M113.460162. Epub 2013 Jun 7. J Biol Chem. 2013. PMID: 23749994 Free PMC article.
-
Both hemolytic anemia and malaria parasite-specific factors increase susceptibility to Nontyphoidal Salmonella enterica serovar typhimurium infection in mice.Infect Immun. 2010 Apr;78(4):1520-7. doi: 10.1128/IAI.00887-09. Epub 2010 Jan 25. Infect Immun. 2010. PMID: 20100860 Free PMC article.
-
A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies.J Exp Med. 2003 Sep 15;198(6):869-75. doi: 10.1084/jem.20030085. Epub 2003 Sep 8. J Exp Med. 2003. PMID: 12963693 Free PMC article.
-
Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain.Infect Immun. 2004 Oct;72(10):5840-9. doi: 10.1128/IAI.72.10.5840-5849.2004. Infect Immun. 2004. PMID: 15385485 Free PMC article.
-
Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.Vaccine. 2010 Mar 19;28(14):2580-92. doi: 10.1016/j.vaccine.2010.01.019. Epub 2010 Jan 22. Vaccine. 2010. PMID: 20097151 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials